SCHEMBL11901907

SCHEMBL11901907

C[C@H](NC(=O)OC(C)(C)C)C(=O)N(NC1CC1)c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.40
CTSK P43235 2/20 0.40
POLB P06746 1/20 0.39
SCN9A Q15858 2/20 0.38
PABPC1 P11940 1/20 0.38
CACNA1B Q00975 2/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
KCNQ4 P56696 1/20 0.35
KCNQ5 Q9NR82 1/20 0.35
HRH2 P25021 2/20 0.35
HRH1 P35367 2/20 0.35
KDM4D Q6B0I6 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.34
KLK7 P49862 1/20 0.34
EPHX2 P34913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11901739 0.96 CTSS (0.39) CTSSCTSKPOLBSCN9APABPC1
SCHEMBL11901764 0.92 CTSS (0.42) CTSSCTSKPOLBSCN9APABPC1
SCHEMBL11900734 0.87 CTSS (0.42) CTSSCTSKPOLBSCN9AKCNQ4
SCHEMBL11902408 0.85 AAK1 (0.37) SCN9ACACNA1BKMT2AMEN1HRH2
SCHEMBL22312263 0.79 CTSS (0.43) CTSSCTSKSCN9AKMT2AMEN1
SCHEMBL11901926 0.75 KMT2A (0.39) CTSSCTSKSCN9AKMT2AMEN1
SCHEMBL21180491 0.71 TRPA1 (0.48) CTSSCTSKALDH1A1MAPTEPHX2
SCHEMBL3871050 0.71 TRPA1 (0.48) CTSSCTSKALDH1A1MAPTEPHX2
SCHEMBL25355464 0.70 MEN1 (0.40) CTSSCTSKPOLBSCN9AKMT2A
SCHEMBL26014534 0.70 MEN1 (0.40) CTSSCTSKPOLBSCN9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 CTSS 2609/4885CTSK 1821/4885POLB 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.